Here are four takeaways:
1. During the aforementioned time frame, the market is anticipated to increase at a compound annual growth rate of 55.52 percent.
2. Physicians’ hesitation to prescribe biosimilars will pose as a barrier to market growth.
3. Leading vendors include Sandoz, Hospira, Teva Pharmaceuticals and STADA.
4. Other market vendors are Celltrion, Biocon, Amegen, Apotex and Aspen, among several others.
More articles on quality & infection control:
Are patients hospitalized for infections at greater risk of suicide? 8 takeaways
3 tips to improve nurse safety
STAT: Is it impeccable timing or do biotech executives have the upper hand in the trading game?
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.